Latest research on Avastin

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Avastin indications

The majority of debate over Avastin is about breast cancer because, in 2011, the US Food and Drug Administration (FDA) revoked the approval of Avastin for breast cancer treatment in the absence of decisive therapeutic benefit; however, several clinical trials suggested that Avastin can be effective in breast cancer treatment [6, 7]. [source, 2015]
For example, one of the main reasons why the US FDA revoked the approval of Avastin for treating advanced breast cancer is the high rate of side-effects when bevacizumab was applied [46]. [source, 2015]
Bevacizumab, the active substance of Avastin, is a recombinant humanized IgG1 monoclonal antibody with multiple cancer indications. [source, 2015]
In response to this, the CATT (Comparison of AMD Treatments Trials) and IVAN (Lucentis and Avastin effective in treating wet AMD) studies aimed to compare the safety and efficacy of using ranibizumab versus bevacizumab [41, 42]. [source, 2015]
There needs to be greater awareness of the potential complications of Avastin among neonatologists and ophthalmologists until further trials indicate that lower doses or different preparations are not only effective but safe. [source, 2015]
In the prospective, observational ARIES (Avastin Registry: Investigation of Effectiveness and Safety)25 study, there was no difference between patients aged <70 years and ≥70 years in terms of PFS both in first line (10.3 versus 9.9 months; HR 1.11) and second line (7.9 versus 7.9 months; HR 0.96). [source, 2015]
SiNPs mass product may be more feasible and cost-effective than monoclonal antibodies such as Avastin or bevacizumab. [source, 2015]
The successful stories of a novel indication of a drug for a new condition include Minoxidil, Viagra, Avastin, and Rituxan [3]. [source, 2015]
Bevacizumab (Avastin) was the first antiangiogenic agent approved by the US Food and Drug Administration (FDA) and exerts its effect by preventing the binding of the VEGF-A ligand to its receptors. [source, 2015]
A Phase III study to evaluate the combined effects of Avastin and chemotherapy in patients with advanced gastric cancer reported that overall survival was worse in patient groups that strongly expressed tumor NRP1 than in patients with low baseline expression levels (Van Cutsem et al., 2012), suggesting that NRP1 is tumorigenic. [source, 2015]